1. A conformation-selective monoclonal antibody against a small molecule-stabilised signalling-deficient form of TNF.
- Author
-
Lightwood DJ, Munro RJ, Porter J, McMillan D, Carrington B, Turner A, Scott-Tucker A, Hickford ES, Schmidt A, Fox D 3rd, Maloney A, Ceska T, Bourne T, O'Connell J, and Lawson ADG
- Subjects
- Antibodies, Monoclonal pharmacology, Cells, Cultured, Crystallography, X-Ray, Epitopes chemistry, Epitopes metabolism, HEK293 Cells, Humans, Models, Molecular, Multiprotein Complexes chemistry, Protein Binding drug effects, Protein Conformation drug effects, Receptors, Tumor Necrosis Factor, Type I chemistry, Signal Transduction drug effects, Small Molecule Libraries chemistry, Small Molecule Libraries pharmacology, Tumor Necrosis Factor-alpha chemistry, Antibodies, Monoclonal metabolism, Multiprotein Complexes metabolism, Receptors, Tumor Necrosis Factor, Type I metabolism, Small Molecule Libraries metabolism, Tumor Necrosis Factor-alpha metabolism
- Abstract
We have recently described the development of a series of small-molecule inhibitors of human tumour necrosis factor (TNF) that stabilise an open, asymmetric, signalling-deficient form of the soluble TNF trimer. Here, we describe the generation, characterisation, and utility of a monoclonal antibody that selectively binds with high affinity to the asymmetric TNF trimer-small molecule complex. The antibody helps to define the molecular dynamics of the apo TNF trimer, reveals the mode of action and specificity of the small molecule inhibitors, acts as a chaperone in solving the human TNF-TNFR1 complex crystal structure, and facilitates the measurement of small molecule target occupancy in complex biological samples. We believe this work defines a role for monoclonal antibodies as tools to facilitate the discovery and development of small-molecule inhibitors of protein-protein interactions.
- Published
- 2021
- Full Text
- View/download PDF